BRIEF—Boehringer's Shanghai biopharmaceuticals facility wins new customer

China’s BeiGene has entered into a commercial supply agreement with privately held German firm Boehringer Ingelheim.

The investigational checkpoint inhibitor tislelizumab will be manufactured at Boehringer’s Shanghai manufacturing site.

BeiGene also obtained certain preferred rights for future capacity expansion by Boehringer Ingelheim in China.

BeiGene is also building a manufacturing facility for biologics commercial supply in Guangzhou, aimed at expanding capacity to meet anticipated demand for tislelizumab and other biologics in our pipeline.

In a separate deal, the Beijing-based biotech  announced days ago that it was in-licensing Mirati Therapeutics’ sitravatinib in parts of Asia.